medigraphic.com

2021, Number 1

<< Back Next >>

Rev Mex Anest 2021; 44 (1)

Neuropathic pain in insulin-dependent diabetic patients

Pérez-Guirola Y, Lombas-Rojas A, Cordero-Escobar I

Language: Spanish
References: 33
Page: 51-54
PDF size: 244.05 Kb.


ABSTRACT

Introduction: Neuropathic pain is complex and despite the pharmacological and non-pharmacological advances of recent years, it is the main cause of suffering in insulin-dependent diabetic patients. Objective: To update a non-systematic review of the literature on neuropathic pain in the insulin-dependent diabetic patient. Material and methods: A literature search was conducted on August 3 of 2019 in the PubMed databases of the National Medical Library of the United States (NLM), with the following English-language descriptors: insulin-dependent diabetes mellitus AND neuropathic pain, which offered a total of 133 publications. When the filter was activated in humans, 11 articles were maintained. With the filter in the last five years, full text remained one whose title is not related to the proposed project. Conclusions: The general insulin-dependent diabetic patient presents with neuropathic pain of varying intensity, which affects their quality of life and requires specialized treatment.


REFERENCES

  1. Pérez C, Ribera MV, Gálvez R, Micó JA, Barutell C, Failde I, et al. High prevalence of confirmed, butalsoof potential and believed, neuropathic pain in pain clinics. Eur J Pain. 2013;17:347-356.

  2. Samper BD, Monerris TM, Homs RM, Soler PM. Etiología y manejo de la neuropatía diabética dolorosa. Rev Soc Esp Dolor. 2010;17:286-298.

  3. Flórez S, León M, Torres M, Reyes F, Serpa JC, Ríos AM. Manejo farmacológico del dolor neuropático. Rev Col Anest. 2009;37:356-372.

  4. Pérez C, Ribera MV, Gálvez R, Micó JA, Barutell C, Failde I, et al. High prevalence of confirmed, but also of potential and believed, neuropathic pain in pain clinics. Eur J Pain. 2013;17:347-356.

  5. Camperos SM. Revista médica. Clínica Las Condes. 2014;25:602-609.

  6. Declaration of Montreal. Declaration that access to pain management is a fundamental human right. [On line]. Consulted: June 2019. URL Available in: http://www.iasp-pain.org/DeclarationofMontreal?navItemNumber=582.

  7. Maier C, Baron R, Tölle TR, Binder A, Birbaumer N, Birklein F, et al. Quantitative somatosensory abnormalities in 1,236 patients with different neuropathic pain syndromes. Pain. 2010;150:384-385.

  8. Gaspar AT, Antunes F. Type 1 complex regional pain syndrome. Acta Med Port. 2011;24:1031-1040.

  9. Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DL, Bouhassira D, et al. Neuropathic pain: an updated grading system for research and clinical practice. Pain. 2016;157(8):1599-606.

  10. Escaño-Polanco FM, Odriozola A, Davidson J, Pedrosa H, Fuente G, Márquez G, et al. Consenso de expertos para el manejo de la neuropatía diabética. Rev ALAD. 2016;6:121-150.

  11. Moriyama Y, Hiasa M, Sakamoto S, Omote H, Nomura M. Vesicular nucleotide transporter (VNUT): appearance of an actress on the stage of purinergic signaling. Purinergic Signal. 2017;13:387-404.

  12. Spallone V. Management of painful diabetic neuropathy: guideline guidance or jungle? Curr Diab Rep. 2012;12:403-413.

  13. Capmourteres EM, Finkel D. Psychotropic coadjuvants in pain treatment. Vertex. 2002;48:100-110.

  14. Zarei M, Sabetkasaei M, Moini Zanjani T. Paroxetine attenuates the development and existing pain in a rat model of neurophatic pain. Iran Biomed J. 2014;18:94-100.

  15. Mick G, Baron R, Finnerup NB. What is localized neuropathic pain? A first proposal to characterize and define a widely used term. Pain Manage. 2012;1:71-77.

  16. Haanpaa M, Treede R.D. Diagnosis and classification of neuropathic pain. IASP Pain Clinical Updates. 2010;18: [On Line]. Consulted. 15 October of 2019. URL. https://www.iasp-pain.org/PublicationsNews/NewsletterIssue.aspx?ItemNumber=2083.

  17. Saig G. Diabetic neuropathy. Handb Clin Neurol. 2013;115:579-589.

  18. González-Escalada JR, Rodríguez MJ, Camba MA. Recomendaciones para el tratamiento del dolor neuropático. Rev Soc Esp Dolor. 2009;16:445-467.

  19. Baron R. Neuropathic pain: a clinical perspective. Handb Exp Pharmacol. 2009;194:3-30.

  20. Brown MJ, Bird SJ, Watling S, Kaleta H, Hayes L, Eckert S, et al. Zenarest study. Natural progression of diabetic peripheral neuropathy in the Zenarestat study population. Diabetes Care. 2009;27:1153-1159.

  21. Schiavon F, Circhetta C, Dani L. The diabetic hand. Rheumatism. 2010;56:139-142.

  22. Mota M, Panus C, Mota E, Sfredel V, Patrascu A, Vanghelie L, et al. Hand abnormalities of the patients with diabetes mellitus. Rom J Intern Med. 2011;38-39:89-95.

  23. Rodríguez JM, Menéndez JR, Trujillo Y. Radicales libres en la biomedicina y estrés oxidativo. Rev Cub Med Milit. 2011;30:15-20.

  24. Pop-Busui R, Boulton JA, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic Neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40:136-154.

  25. American Diabetes Association. Microvascular complications and foot care. Diabetes Care. 2017;40:588-598.

  26. Tesfaye S, Vileikyte L, Rayman G, Sindrup SH, Perkins BA, Baconja M, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27:629-638.

  27. De Dios del Valle R. González Torrejón M, Sacristán Rodea A. Manejo del dolor neuropático: la gabapentina como opción. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1131-57682001000400006.

  28. Dy SM, Bennett WL, Sharma R, Zhang A, Waldfogel JM, Nesbit SA, et al. Complications and Treating Symptoms of Diabetic Peripheral Neuropathy. Comparative Effectiveness Review No. 187. (Prepared by the Johns Hopkins University Evidence-based Practice Center under Contract No. 290-2015-00006-I.) AHRQ Publication No. 17-EHC005-EF. Rockville, MD: Agency for Healthcare Research and Quality; March 2017. [On line] Consulted: 30 October of 2019. URL: https://www.ncbi.nlm.nih.gov/books/NBK442335/pdf/Bookshelf_NBK442335.pd.

  29. Wiffen PJ, Derry S, Bell RF, Rice ASC, Tölle T, Phillips T, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews. 2017;6:CD007938.

  30. Derry S, Wiffen PJ, Moore R, Quinlan J. Topical lidocaine for neuropathic pain in adults. Cochrane Database of Systematic Reviews. 2014;7:CD010958.

  31. Oliveros-Lijap L, Ávila-Espinoza P, Ulloa V, Bernabe-Ortiz A. Calidad de vida en pacientes con neuropatía diabética periférica: estudio transversal en Lima, Perú. Acta Med Peru. 2018;35(3):160-7

  32. FDA. Food and drugs administration. [On line] Consulted: 23 November of 2019. URL. https://www.registrarcorp.com/fda-facility-registration/?utm_source=google&utm_medium=cpc&utm_term=+fda++agency&utm_content=1054397892&utm_campaign=39400842&matchtype=b&device=c&gclid=EAIaIQobChMIk4OfuZHA5wIVVoNaBR0L6AmIEAAYASAAEgKVhPD_BwE&step=1.

  33. Agencia Española de Medicamentos. [En línea] Consultado: 23 Noviembre de 2019. Disponible en: https://www.aemps.gob.es/informa/alertas/home.htm.




2020     |     www.medigraphic.com